Soligenix Bolsters Medical Advisory Board to Advance HyBryte Phase 3 Development for CTCL Treatment

Soligenix Inc., a late-stage biopharmaceutical company trading on NASDAQ under the symbol SNGX, has announced significant updates to its U.S. Medical Advisory Board for cutaneous T-cell lymphoma. This strategic move aims to support the ongoing Phase 3 development of HyBryte, the company's synthetic hypericin photodynamic therapy treatment for CTCL patients. The advisory board comprises leading dermatologic and oncologic experts who will provide critical guidance as Soligenix advances both regulatory and commercialization activities for this innovative therapy.

The importance of this development lies in addressing a significant unmet medical need for CTCL patients worldwide. Cutaneous T-cell lymphoma represents a rare form of cancer that affects the skin, and current treatment options remain limited for many patients. HyBryte represents a novel approach as a photodynamic therapy that utilizes safe visible light, potentially offering a new therapeutic option where few exist. President and CEO Christopher J. Schaber, PhD, emphasized that the addition of new key opinion leaders reinforces the program's clinical depth and demonstrates the company's commitment to bringing this treatment to patients globally.

Soligenix's Specialized BioTherapeutics business segment is developing HyBryte as a potential treatment for CTCL, with the company having successfully completed its second Phase 3 study. The company now seeks regulatory approvals to support potential commercialization worldwide. The development significance extends beyond CTCL, as Soligenix is also exploring expansion of synthetic hypericin into psoriasis treatment, representing potential broader applications for this technology platform. Additional information about the company's developments can be found at https://ibn.fm/SNGX.

The implications of this advisory board update extend to both patient care and the biopharmaceutical industry. For patients suffering from CTCL, the advancement of HyBryte through Phase 3 development brings hope for a new treatment modality that could improve quality of life and treatment outcomes. For the medical community, the involvement of leading experts in dermatology and oncology ensures that the development pathway incorporates current best practices and clinical insights. The broader biopharmaceutical industry may benefit from the successful development of this photodynamic therapy approach, potentially validating similar treatment mechanisms for other conditions.

Soligenix's comprehensive approach includes multiple development programs across its business segments. Beyond HyBryte, the company is advancing its first-in-class innate defense regulator technology, dusquetide, for inflammatory diseases including oral mucositis in head and neck cancer patients. The company's Public Health Solutions segment includes vaccine development programs supported by government funding from agencies including the National Institute of Allergy and Infectious Diseases, the Defense Threat Reduction Agency, and the Biomedical Advanced Research and Development Authority. These parallel developments demonstrate the company's broader commitment to addressing significant medical challenges across multiple therapeutic areas.